{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T03:25:59Z","timestamp":1791861959440,"version":"4.3.4"},"reference-count":43,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,2,5]],"date-time":"2021-02-05T00:00:00Z","timestamp":1612483200000},"content-version":"vor","delay-in-days":766,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Indian Journal of Medical Microbiology"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.4103\/ijmm.ijmm_19_189","type":"journal-article","created":{"date-parts":[[2019,9,20]],"date-time":"2019-09-20T06:17:20Z","timestamp":1568960240000},"page":"34-41","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"title":["Will Ceftazidime\/Avibactam Plus Aztreonam be Effective for NDM and OXA-48-Like Producing Organisms: Lessons Learnt from In vitro Study"],"prefix":"10.1016","volume":"37","author":[{"given":"Agila Kumari","family":"Pragasam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Balaji","family":"Veeraraghavan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baby Abirami","family":"Shankar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yamuna Devi","family":"Bakthavatchalam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Mathuram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biju","family":"George","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Binila","family":"Chacko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pritish","family":"Korula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shalini","family":"Anandan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.4103\/ijmm.IJMM_19_189_bib1","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1089\/mdr.2016.0043","article-title":"Minocycline and tigecycline: What is their role in the treatment of carbapenem-resistant gram-negative organisms?","volume":"23","author":"Shankar","year":"2017","journal-title":"Microb Drug Resist"},{"key":"10.4103\/ijmm.IJMM_19_189_bib2","doi-asserted-by":"crossref","first-page":"e161","DOI":"10.1097\/INF.0000000000001499","article-title":"Clinical and bacterial risk factors for mortality in children with carbapenem-resistant Enterobacteriaceae bloodstream infections in India","volume":"36","author":"Nabarro","year":"2017","journal-title":"Pediatr Infect Dis J"},{"key":"10.4103\/ijmm.IJMM_19_189_bib3","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1128\/MMBR.00078-15","article-title":"Klebsiella pneumoniae: Going on the offense with a strong defense","volume":"80","author":"Paczosa","year":"2016","journal-title":"Microbiol Mol Biol Rev"},{"key":"10.4103\/ijmm.IJMM_19_189_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.jiph.2019.03.023","article-title":"Emergence of ST147 Klebsiella pneumoniae carrying blaNDM-7 on IncA\/C2 with ompK35 and ompK36 mutations in India","author":"Shankar","year":"2019","journal-title":"J Infect Public Health"},{"key":"10.4103\/ijmm.IJMM_19_189_bib5","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1080\/20477724.2017.1340128","article-title":"Carbapenem resistant Klebsiella pneumoniae isolated from bloodstream infection: Indian experience","volume":"111","author":"Veeraraghavan","year":"2017","journal-title":"Pathog Glob Health"},{"key":"10.4103\/ijmm.IJMM_19_189_bib6","doi-asserted-by":"crossref","first-page":"4","DOI":"10.4172\/2332-0877.1000293","article-title":"Mechanisms of carbapenem resistance in K. pneumoniae and E. coli from bloodstream infections in India","volume":"4","author":"Sharma","year":"2016","journal-title":"J Infect Dis Ther"},{"key":"10.4103\/ijmm.IJMM_19_189_bib7","doi-asserted-by":"crossref","first-page":"421","DOI":"10.4103\/ijmm.IJMM_16_386","article-title":"Identification of carbapenemase-mediated resistance among Enterobacteriaceae bloodstream isolates: A molecular study from India","volume":"35","author":"Mohanty","year":"2017","journal-title":"Indian J Med Microbiol"},{"key":"10.4103\/ijmm.IJMM_19_189_bib8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.9734\/JAMB\/2018\/43928","article-title":"Endemicity of OXA-48 and NDM-1 carbapenemase producing Klebsiella pneumoniae and Escherichia coli from a tertiary hospital in Varanasi, India","volume":"12","author":"Filgona","year":"2018","journal-title":"J Adv Microbiol"},{"key":"10.4103\/ijmm.IJMM_19_189_bib9","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.12688\/f1000research.11532.1","article-title":"Recent advances in the understanding and management of Klebsiella pneumoniae","volume":"6","author":"Calfee","year":"2017","journal-title":"F1000Res"},{"key":"10.4103\/ijmm.IJMM_19_189_bib10","first-page":"13","article-title":"Extremely high mortality rates in patients with carbapenem-resistant, hypermucoviscous Klebsiella pneumoniae blood stream infections","volume":"66","author":"Shankar","year":"2018","journal-title":"J Assoc Physicians India"},{"key":"10.4103\/ijmm.IJMM_19_189_bib11","doi-asserted-by":"crossref","first-page":"3601","DOI":"10.1128\/AAC.03007-15","article-title":"Combination regimens for treatment of carbapenem-resistant Klebsiella pneumoniae bloodstream infections","volume":"60","author":"Gomez-Simmonds","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.4103\/ijmm.IJMM_19_189_bib12","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.drup.2017.11.002","article-title":"An update on \u03b2-lactamase inhibitor discovery and development","volume":"36","author":"Docquier","year":"2018","journal-title":"Drug Resist Updat"},{"key":"10.4103\/ijmm.IJMM_19_189_bib13","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1039\/C8MD00342D","article-title":"B-lactam\/\u03b2-lactamase inhibitor combinations: An update","volume":"9","author":"Tehrani","year":"2018","journal-title":"Medchemcomm"},{"issue":"Suppl 1","key":"10.4103\/ijmm.IJMM_19_189_bib14","doi-asserted-by":"crossref","first-page":"S419","DOI":"10.1093\/ofid\/ofy210.1201","article-title":"1370. Cefepime\/VNRX-5133 broad-spectrum activity is maintained against emerging KPC- and PDC-variants in multidrug-resistant K. pneumoniae and P. aeruginosa","volume":"5","author":"Daigle","year":"2018","journal-title":"Open Forum Infect Dis"},{"key":"10.4103\/ijmm.IJMM_19_189_bib15","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1093\/cid\/ciw243","article-title":"Ceftazidime\/Avibactam and ceftolozane\/Tazobactam: Second-generation \u03b2-lactam\/\u03b2-lactamase inhibitor combinations","volume":"63","author":"van Duin","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.4103\/ijmm.IJMM_19_189_bib16","doi-asserted-by":"crossref","first-page":"e00592-18","DOI":"10.1128\/AAC.00592-18","article-title":"In vitro activity of ceftazidime-avibactam and aztreonam-avibactam against OXA-48-carrying Enterobacteriaceae isolated as part of the international network for optimal resistance monitoring (INFORM) global surveillance program from 2012 to 2015","volume":"62","author":"Kazmierczak","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.4103\/ijmm.IJMM_19_189_bib17","doi-asserted-by":"crossref","first-page":"2849","DOI":"10.1128\/AAC.02286-15","article-title":"Activity of ceftazidime-avibactam against extended-spectrum- and AmpC \u03b2-lactamase-producing Enterobacteriaceae collected in the INFORM global surveillance study from 2012 to 2014","volume":"60","author":"Karlowsky","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.4103\/ijmm.IJMM_19_189_bib18","doi-asserted-by":"crossref","first-page":"e02431-18","DOI":"10.1128\/AAC.02431-18","article-title":"Results from the China antimicrobial surveillance network (CHINET) in 2017 of the In vitro activities of ceftazidime-avibactam and ceftolozane-tazobactam against clinical isolates of Enterobacteriaceae and Pseudomonas aeruginosa","volume":"63","author":"Yin","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.4103\/ijmm.IJMM_19_189_bib19","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1093\/cid\/ciw636","article-title":"Clinical outcomes, drug toxicity, and emergence of ceftazidime-avibactam resistance among patients treated for carbapenem-resistant Enterobacteriaceae infections","volume":"63","author":"Shields","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.4103\/ijmm.IJMM_19_189_bib20","doi-asserted-by":"crossref","first-page":"e00449-17","DOI":"10.1128\/AAC.00449-17","article-title":"Multicenter study of outcomes with ceftazidime-avibactam in patients with carbapenem-resistant Enterobacteriaceae infections","volume":"61","author":"King","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.4103\/ijmm.IJMM_19_189_bib21","doi-asserted-by":"crossref","first-page":"e01964-16","DOI":"10.1128\/AAC.01964-16","article-title":"Ceftazidime-avibactam as salvage therapy for infections caused by carbapenem-resistant organisms","volume":"61","author":"Temkin","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.4103\/ijmm.IJMM_19_189_bib22","doi-asserted-by":"crossref","first-page":"e02497-17","DOI":"10.1128\/AAC.02497-17","article-title":"Pneumonia and renal replacement therapy are risk factors for ceftazidime-avibactam treatment failures and resistance among patients with carbapenem-resistant Enterobacteriaceae infections","volume":"62","author":"Shields","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.4103\/ijmm.IJMM_19_189_bib23","doi-asserted-by":"crossref","first-page":"e00883-17","DOI":"10.1128\/AAC.00883-17","article-title":"Ceftazidime-avibactam is superior to other treatment regimens against carbapenem-resistant Klebsiella pneumoniae bacteremia","volume":"61","author":"Shields","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.4103\/ijmm.IJMM_19_189_bib24","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.ijid.2017.03.021","article-title":"Clinical efficacy of ceftazidime\/avibactam versus other active agents for the treatment of bacteremia due to carbapenemase-producing Enterobacteriaceae in hematologic patients","volume":"59","author":"Cast\u00f3n","year":"2017","journal-title":"Int J Infect Dis"},{"key":"10.4103\/ijmm.IJMM_19_189_bib25","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1093\/cid\/cix783","article-title":"Antibacterial resistance leadership G. Colistin versus ceftazidime-avibactam in the treatment of infections due to carbapenem-resistant Enterobacteriaceae","volume":"66","author":"Van Duin","year":"2018","journal-title":"Clin Infect Dis"},{"key":"10.4103\/ijmm.IJMM_19_189_bib26","doi-asserted-by":"crossref","first-page":"3170","DOI":"10.1093\/jac\/dky295","article-title":"Effectiveness of ceftazidime\/avibactam as salvage therapy for treatment of infections due to OXA-48 carbapenemase-producing Enterobacteriaceae","volume":"73","author":"Sousa","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"10.4103\/ijmm.IJMM_19_189_bib27","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1080\/17425255.2019.1563071","article-title":"Novel \u03b2-lactam-\u03b2-lactamase inhibitor combinations: Expectations for the treatment of carbapenem-resistant gram-negative pathogens","volume":"15","author":"Karaiskos","year":"2019","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.4103\/ijmm.IJMM_19_189_bib28","series-title":"Performance Standards for Antimicrobial Susceptibility Testing. Informational Supplement. CLSI Document M100-S29","year":"2019"},{"key":"10.4103\/ijmm.IJMM_19_189_bib29","doi-asserted-by":"crossref","first-page":"433","DOI":"10.4103\/0255-0857.195376","article-title":"Molecular characterisation of antimicrobial resistance in Pseudomonas aeruginosa and Acinetobacter baumannii during 2014 and 2015 collected across India","volume":"34","author":"Pragasam","year":"2016","journal-title":"Indian J Med Microbiol"},{"key":"10.4103\/ijmm.IJMM_19_189_bib30","doi-asserted-by":"crossref","first-page":"445","DOI":"10.4103\/ijmm.IJMM_17_189","article-title":"An update on technical, interpretative and clinical relevance of antimicrobial synergy testing methodologies","volume":"35","author":"Laishram","year":"2017","journal-title":"Indian J Med Microbiol"},{"key":"10.4103\/ijmm.IJMM_19_189_bib31","doi-asserted-by":"crossref","first-page":"334","DOI":"10.4103\/ijmm.IJMM_18_326","article-title":"Newer \u03b2-Lactam\/\u03b2-Lactamase inhibitor for multidrug-resistant gram-negative infections: Challenges, implications and surveillance strategy for India","volume":"36","author":"Veeraraghavan","year":"2018","journal-title":"Indian J Med Microbiol"},{"key":"10.4103\/ijmm.IJMM_19_189_bib32","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/S1473-3099(13)70190-7","article-title":"Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases","volume":"13","author":"Munoz-Price","year":"2013","journal-title":"Lancet Infect Dis"},{"key":"10.4103\/ijmm.IJMM_19_189_bib33","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1007\/s10096-017-3112-7","article-title":"OXA-48-like carbapenemases producing Enterobacteriaceae in different niches","volume":"37","author":"Mairi","year":"2018","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.4103\/ijmm.IJMM_19_189_bib34","doi-asserted-by":"crossref","first-page":"895","DOI":"10.3389\/fmicb.2016.00895","article-title":"Global dissemination of carbapenemase-producing Klebsiella pneumoniae: Epidemiology, genetic context, treatment options, and detection methods","volume":"7","author":"Lee","year":"2016","journal-title":"Front Microbiol"},{"key":"10.4103\/ijmm.IJMM_19_189_bib35","doi-asserted-by":"crossref","first-page":"344","DOI":"10.4103\/ijmm.IJMM_18_294","article-title":"Dominance of international high-risk clones in carbapenemase-producing Pseudomonas aeruginosa: Multicentric molecular epidemiology report from India","volume":"36","author":"Pragasam","year":"2018","journal-title":"Indian J Med Microbiol"},{"key":"10.4103\/ijmm.IJMM_19_189_bib36","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/j.ijantimicag.2018.07.011","article-title":"Assessing the in vitro activity of ceftazidime\/avibactam and aztreonam among carbapenemase-producing Enterobacteriaceae: Defining the zone of hope","volume":"52","author":"Avery","year":"2018","journal-title":"Int J Antimicrob Agents"},{"key":"10.4103\/ijmm.IJMM_19_189_bib37","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.diagmicrobio.2017.05.009","article-title":"Synergistic activity of ceftazidime-avibactam and aztreonam against serine and metallo-\u03b2-lactamase-producing gram-negative pathogens","volume":"88","author":"Wenzler","year":"2017","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.4103\/ijmm.IJMM_19_189_bib38","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1186\/s13756-018-0435-9","article-title":"In vitro and in vivo bactericidal activity of ceftazidime-avibactam against carbapenemase-producing Klebsiella pneumoniae","volume":"7","author":"Zhang","year":"2018","journal-title":"Antimicrob Resist Infect Control"},{"key":"10.4103\/ijmm.IJMM_19_189_bib39","doi-asserted-by":"crossref","first-page":"e02243-16","DOI":"10.1128\/AAC.02243-16","article-title":"Can ceftazidime-avibactam and aztreonam overcome \u03b2-Lactam resistance conferred by metallo-\u03b2-Lactamases in Enterobacteriaceae?","volume":"61","author":"Marshall","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.4103\/ijmm.IJMM_19_189_bib40","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/j.ijantimicag.2019.03.006","article-title":"Where should antibiotic gradient diffusion strips be crossed to assess synergy? A comparison of the standard method with a novel method using steady-state antimicrobial concentrations","volume":"53","author":"Motos","year":"2019","journal-title":"Int J Antimicrob Agents"},{"key":"10.4103\/ijmm.IJMM_19_189_bib41","doi-asserted-by":"crossref","first-page":"e01008","DOI":"10.1128\/AAC.01008-17","article-title":"Ceftazidime-avibactam and aztreonam, an interesting strategy to overcome \u03b2-Lactam resistance conferred by metallo-\u03b2-Lactamases in Enterobacteriaceae and Pseudomonas aeruginosa","volume":"61","author":"Davido","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.4103\/ijmm.IJMM_19_189_bib42","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1093\/jac\/dkx496","article-title":"Clinical outcomes after combination treatment with ceftazidime\/avibactam and aztreonam for NDM-1\/OXA-48\/CTX-M-15-producing Klebsiella pneumoniae infection","volume":"73","author":"Shaw","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"10.4103\/ijmm.IJMM_19_189_bib43","doi-asserted-by":"crossref","first-page":"e02463-18","DOI":"10.1128\/AAC.02463-18","article-title":"Successful treatment of bacteremia due to NDM-1-producing Morganella morganii with aztreonam and ceftazidime-avibactam combination in a pediatric patient with hematologic malignancy","volume":"63","author":"Hobson","year":"2019","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Indian Journal of Medical Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0255085720312342?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0255085720312342?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T19:17:17Z","timestamp":1759346237000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0255085720312342"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["S0255085720312342"],"URL":"https:\/\/doi.org\/10.4103\/ijmm.ijmm_19_189","relation":{},"ISSN":["0255-0857"],"issn-type":[{"value":"0255-0857","type":"print"}],"subject":[],"published":{"date-parts":[[2019,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Will Ceftazidime\/Avibactam Plus Aztreonam be Effective for NDM and OXA-48-Like Producing Organisms: Lessons Learnt from In vitro Study","name":"articletitle","label":"Article Title"},{"value":"Indian Journal of Medical Microbiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.4103\/ijmm.IJMM_19_189","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2019 Indian Journal of Medical Microbiology. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}